GSC The List

Post Reply
Forum Home > I > IBS/IBD + (See Also BOWEL DISORDERS)

[email protected]
Site Owner
Posts: 1174

Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3232190/?toolubmed

Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/

The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. (full – 2011) http/www.nature.com/mi/journal/v4/n5/full/mi201118a.html

A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. (full – 2011) http/onlinelibrary.wiley.com/doi/10.1111/j.1365-2982.2011.01742.x/full

Pharmacogenetic Trial of a Cannabinoid Agonist Shows Reduced Fasting Colonic Motility in Patients with Non-Constipated Irritable Bowel Syndrome. (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3202649/

Cannabis use amongst patients with inflammatory bowel disease. (abst – 2011) http/www.ncbi.nlm.nih.gov/pubmed/21795981

Role of cannabinoid receptors and RAGE in inflammatory bowel disease. (abst – 2011) http/www.unboundmedicine.com/medline/ebm/record/21472688/abstract/Role_of_cannabinoid_receptors_and_RAGE_in_inflammatory_bowel_disease_

Cannabis Use Common Among Patients With Inflammatory Bowel Disease, Study Says (news – 2011) http/norml.org/news/2011/08/04/cannabis-use-common-among-patients-with-inflammatory-boweldisease-study-says

Irritable bowel syndrome: a dysfunction of the endocannabinoid system? (full – 2012) http/www.gastrojournal.org/article/S0016-5085%2811%2901710-0/fulltext

The Gastrointestinal Pharmacology of Cannabinoids: Focus on Motility. (full – 2012) http/content.karger.com/produktedb/produkte.asp?DOI=000339072&typdf

Genetic Epidemiology and Pharmacogenetics in Irritable Bowel Syndrome. (full - 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3362100/

Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome (full – 2012) http/ajpgi.physiology.org/content/302/10/G1075

Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3775711/

Gut microbiota and the development of obesity. (full – 2012) http/scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-16112012000500007&lng=en&nrm=iso&tlng=en

The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. (abst – 2012) http/www.ncbi.nlm.nih.gov/pubmed/22917662?dopt=Abstract

Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview. (abst – 2012) http/www.ncbi.nlm.nih.gov/pubmed/22815234

The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. (abst – 2012) http/www.ncbi.nlm.nih.gov/pubmed/22917662

Agents that act luminally to treat diarrhoea and constipation. (abst – 2012) http/www.ncbi.nlm.nih.gov/pubmed/22945441

Cannabis Finds Its Way into Treatment of Crohn's Disease. (full – 2013) http/www.karger.com/Article/Pdf/356512

Role of endogenous cannabinoid system in the gut. (full – 2013) http/www.actaps.com.cn/qikan/manage/wenzhang/2013-4-12.pdf

Irritable Bowel Syndrome and Migraine: Bystanders or Partners? (full – 2013) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3714407/

Endocannabinoid and Cannabinoid-Like Fatty Acid Amide Levels Correlate with Pain-Related Symptoms in Patients with IBS-D and IBS-C: A Pilot Study. (full – 2013) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3874007/

Cannabinoid Receptor 1 Gene and Irritable Bowel Syndrome: Phenotype and Quantitative Traits. (full – 2013) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3602676/

Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis. (full – 2013) http/www.nature.com/labinvest/journal/v93/n3/full/labinvest2012177a.html

Industrial hemp decreases intestinal motility stronger than indian hemp in mice. (link to PDF – 2013) http/www.europeanreview.org/article/3266

Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/23415610

Preventive and therapeutic oral administration of the pentacyclic triterpene α,β-amyrin ameliorates dextran sulfate sodium-induced colitis in mice: The relevance of cannabinoid system. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/23454360

Cannabidiol in inflammatory bowel diseases: a brief overview. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/22815234

Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/24238999

Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/24275607

Decreased Enteric Fatty Acid Amide Hydrolase Activity is Associated with Colonic Inertia in Slow Transit Constipation (abst – 2013) http/onlinelibrary.wiley.com/doi/10.1111/jgh.12346/abstract

Marijuana use patterns among patients with inflammatory bowel disease. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/24185313

Still Believe Nature Got It Wrong? Top 10 Health Benefits of Marijuana (news – 2013) http/www.wakingtimes.com/2013/05/01/still-believe-nature-got-it-wrong-top-10-health-benefits-ofmarijuana/

Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System. (full – 2014) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3951193/

Association of cannabinoid type 1 receptor and fatty acid amide hydrolase genetic polymorphisms in Chinese patients with irritable bowel syndrome. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24444427

Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24460851

Switching cannabinoid response from CB2 agonists to FAAH inhibitors. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24508127

Toward modulation of the endocannabinoid system for treatment of gastrointestinal disease: FAAHster but not "higher". (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24641009

Vagal anandamide signaling via cannabinoid receptor 1 contributes to luminal 5-HT modulation of visceral nociception in rats. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24813296

Ultramicronized palmitoylethanolamide normalizes intestinal motility in a murine model of post-inflammatory accelerated transit: involvement of CB1 receptors and TRPV1. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24818658

The endocannabinoid anandamide regulates the peristaltic reflex by reducing neuroneuronal and neuro-muscular neurotransmission in ascending myenteric reflex pathways in rats. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24911079

Cannabis for inflammatory bowel disease. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24969296

Clinical endocannabinoid deficiency (CECD) revisited: Can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24977967

Potential therapeutic applications of cannabinoids in gastrointestinal and liver diseases: Focus on Δ9-tetrahydrocannabinol pharmacology (abst – 2014) http/onlinelibrary.wiley.com/doi/10.1002/9781118451281.ch7/summary

(Mo1121) Cannabinoid Use Decreases ED Utilization in a Gastroenterology Clinic Population (abst – 2014)

http/www.gastrojournal.org/article/S0016-5085%2814%2962037-0/pdf

(Mo1122) Prevalence and Characterization of Cannabinoid Use in Patients With Gastrointestinal Disorders (abst – 2014) http/www.gastrojournal.org/article/S0016-5085%2814%2962037-0/pdf

Palmitoylethanolamide, a naturally-occurring lipid, is an orally effective intestinal anti-inflammatory agent (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25205418

Medical Marijuana for Digestive Disorders: High Time to Prescribe? (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25199471

Cannabinoids Alleviate Experimentally Induced Intestinal Inflammation by Acting at Central and Peripheral Receptors (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25275313

N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N palmitoylethanolamine levels and counteracts murine colitis (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25384424

Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25499880

Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25531553

No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects (abst – 2015) http://www.ncbi.nlm.nih.gov/pubmed/25599774

A Gut Microbial Metabolite of Linoleic Acid, 10-Hydroxy-cis-12-octadecenoic Acid, Ameliorates Intestinal Epithelial Barrier Impairment Partially via GPR40-MEK-ERK Pathway (abst – 2015) http://www.ncbi.nlm.nih.gov/pubmed/25505251

AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally-restricted manner (abst – 2015) http://onlinelibrary.wiley.com/doi/10.1111/bph.13069/abstract


March 16, 2015 at 3:37 AM Flag Quote & Reply

This topic is closed, no additional posts are allowed.